Peptides et Protéines
Les peptides sont de courtes chaînes d'acides aminés reliées par des liaisons peptidiques, tandis que les protéines sont des chaînes d'acides aminés plus longues et complexes pouvant adopter des structures tridimensionnelles fonctionnelles. Ces deux types de composés sont essentiels à diverses fonctions biologiques, comme la catalyse des réactions (enzymes), la défense immunitaire (anticorps) et la signalisation cellulaire. Les protéines ont une structure hiérarchique comprenant la séquence d’acides aminés, ainsi que les structures secondaire, tertiaire et quaternaire. Les peptides sont utilisés dans les thérapies pharmaceutiques et cosmétiques pour leurs propriétés biologiques spécifiques, notamment dans le traitement des maladies métaboliques ou l’amélioration de la régénération cellulaire. Les protéines, quant à elles, ont des applications en biotechnologie, en nutrition et en médecine régénérative.
Chez CymitQuimica, nous proposons des peptides et des protéines de haute pureté pour la recherche en biotechnologie et les applications thérapeutiques.
3154 produits trouvés pour "Peptides et Protéines"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Semaglutide Impurity 56 (D-Glu 21)
D-Glu(21)-Semaglutide is a semaglutide impurity. The amino acid at position 21 has been replaced by the D-form of the amino acid D-glutamic acid (D-Glu). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.Formule :C187H291N45O59Masse moléculaire :4,113.64 g/mol(S,E)-N-(1-(3-Methylbut-1-enylamino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide
CAS :R-N-(1-(3-methylbut-1-enyl)-1-oxo-3-phenylpropan-2-yl) pyrazine-2-carboxamide is a drug product that is used for the treatment of bacterial infections. The compound is an impurity in the synthesis of other compounds and is also used as an analytical standard. It is synthesized from commercially available starting materials and through custom synthesis. R-N-(1-(3-methylbut-1-enyl)-1--oxo--3--phenylpropan--2--yl)pyrazine--2--carboxamide has been shown to be metabolized by CYP450 enzymes, which are responsible for the metabolism of many drugs. R-(1-(3Methylbut 1Enylamino)-1Oxo 3Phenylpropan 2Yl)Pyrazine 2Carboxamide has not been evaluated as a drug product and therefore does notFormule :C19H22N4O2Degré de pureté :Min. 95%Masse moléculaire :338.4 g/molSemaglutide Impurity 60 (D-Arg 30)
D-Arg(30)-Semaglutide is a semaglutide impurity. The amino acid at position 30 has been replaced by the D-form of the amino acid D-arginine (D-Arg). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molD-Thr(5)-Semaglutide
D-Thr(5)-Semaglutide is a semaglutide impurity. The amino acid at position 5 has been replaced by the D-form of the amino acid D-threonine (D-Thr). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molDes-His(1)-Semaglutide
Des-His(1)-semaglutide is a semaglutide-related impurity. This des-amino acid form has the histidine (His) amino acid from position 1 removed from the peptide chain. Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist used for managing type 2 diabetes and obesity.Formule :C181H284N42O58Masse moléculaire :3,976.5 g/molSemaglutide Impurity 59
D-Arg(28)-Semaglutide is a semaglutide impurity. The amino acid at position 28 has been replaced by the D-form of the amino acid D-arginine (D-Arg). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.
Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molD-Val(10)-Semaglutide
D-Val(10)-Semaglutide is a semaglutide impurity. The amino acid at position 10 has been replaced by the D-form of the amino acid D-valine (D-Val). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.
Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molLisinopril EP Impurity E
CAS :Lisinopril EP Impurity E is an impurity of lisinopril, which is a prescription drug used to treat high blood pressure. This impurity was found in a preparative high performance liquid chromatography (HPLC) and mass spectroscopy analysis of the drug. The molecular weight of Lisinopril EP Impurity E was determined to be 317.2 amu, which corresponds to the molecular formula C7H13NO2. The FT-IR spectrum showed that this impurity has an ammonium group at 1859 cm-1 and butanoic acid at 1647 cm-1.Formule :C21H31N3O5Degré de pureté :Min. 98 Area-%Couleur et forme :PowderMasse moléculaire :405.49 g/molLinear Semaglutide
Linear semaglutide, or simply L-Sema, is the semaglutide compound without the lipid side chain modification. It is essentially a linear version of the peptide.Formule :C152H230N42O47Masse moléculaire :3,397.76 g/molD-Ser-(12)-Semaglutide
D-Ser(12)-Semaglutide is a semaglutide impurity. The amino acid at position 12 has been replaced by the D-form of the amino acid D-serine (D-Ser). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molD-Ala-(19)-Semaglutide
D-Ala(19)-Semaglutide is a semaglutide impurity. The amino acid at position 19 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.
Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molSemaglutide Impurity 101 (D-Glu 3)
D-Glu(3)-Semaglutide is a semaglutide impurity. The amino acid at position 3 has been replaced by the D-form of the amino acid D-glutamic acid (D-Glu). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molD-Ser(11)-Semaglutide
D-Ser(11)-Semaglutide is a semaglutide impurity. The amino acid at position 11 has been replaced by the D-form of the amino acid D-serine (D-Ser). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molDes-Glu(3)-Semaglutide
Des-Glu(3)-semaglutide is a semaglutide-related impurity. This des-amino acid form has got the glutamic acid or glutamate (Glu) amino acid from position 3 removed from the peptide chain. Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist used for managing type 2 diabetes and obesity.Formule :C182H284N44O56Masse moléculaire :3,984.53 g/molD-Asp(9)-Semaglutide
D-Asp(9)-Semaglutide is a semaglutide impurity. The amino acid at position 9 has been replaced by the D-form of the amino acid D-aspartic acid (D-Asp). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.
Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molBortezomib intermediate I
CAS :Bortezomib intermediate I is a metabolite of bortezomib, which is a research and development drug product. Bortezomib intermediate I is an impurity standard for bortezomib. Bortezomib intermediate I can be synthesized from the corresponding compound. It is an analytical standard used in pharmacopoeia and can be used as an API impurity or synthetic material in drug development. Bortezomib intermediate I has a high purity, natural origin, and a niche application. CAS No. 1248339-44-7Formule :C25H36BN5O4Degré de pureté :Min. 95%Couleur et forme :White PowderMasse moléculaire :481.4 g/molSemaglutide Impurity 54 (D-Ala 18)
D-Ala(18)-Semaglutide is a semaglutide impurity. The amino acid at position 18 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.Formule :C187H291N45O59Masse moléculaire :4,113.64 g/molD-Ser(8)-Semaglutide
D-Ser(8)-Semaglutide is a semaglutide impurity. The amino acid at position 8 has been replaced by the D-form of the amino acid D-serine (D-Ser). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.Formule :C187H291N45O59Masse moléculaire :4,113.64 g/mol(R)-3-Methyl-1-(pyrazine- 2-carboxamido)butylboronic acid
The compound is a drug product, analytical, and research material. The molecule has been synthesized and purified by the company's chemists. It is not an API impurity but an impurity standard for HPLC. This compound is a synthetic chemical that does not occur naturally in any living organism. It has been developed for use in drug development and research. The compound was custom synthesized by the company's chemists to meet customer demand for high purity standards of this compound. It is used as a pharmacopoeia standard for HPLC analysis and drug development.Degré de pureté :Min. 95%D-Phe(6)-Semaglutide
D-Phe(6)-Semaglutide is a semaglutide impurity. The amino acid at position 6 has been replaced by the D-form of the amino acid D-phenylalanine (D-Phe). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.Formule :C187H291N45O59Masse moléculaire :4,113.64 g/mol
